Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Elevation Oncology Inc (ELEV)

Elevation Oncology Inc (ELEV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,768
  • Shares Outstanding, K 59,224
  • Annual Sales, $ 0 K
  • Annual Income, $ -44,490 K
  • EBIT $ -49 M
  • EBITDA $ -50 M
  • 60-Month Beta 1.59
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.42
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.82
  • Most Recent Earnings $-0.24 on 05/15/25
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 604.44% ( +174.88%)
  • Historical Volatility 102.99%
  • IV Percentile 82%
  • IV Rank 64.51%
  • IV High 928.22% on 05/12/25
  • IV Low 15.89% on 06/14/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 9
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,396
  • Open Int (30-Day) 1,409

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.23
  • Number of Estimates 5
  • High Estimate -0.18
  • Low Estimate -0.28
  • Prior Year -0.18
  • Growth Rate Est. (year over year) -27.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2716 +18.19%
on 05/16/25
0.3900 -17.69%
on 04/23/25
-0.0510 (-13.71%)
since 04/22/25
3-Month
0.2210 +45.25%
on 04/09/25
0.6450 -50.23%
on 02/24/25
-0.2864 (-47.15%)
since 02/21/25
52-Week
0.2210 +45.25%
on 04/09/25
4.3300 -92.59%
on 05/31/24
-3.4890 (-91.57%)
since 05/22/24

Most Recent Stories

More News
Allogene's Q1 Earnings In Line With Estimates, Sales Nil

Allogene Therapeutics ALLO incurred first-quarter 2025 loss of 28 cents per share, which matched the Zacks Consensus Estimate. In the year-ago period, the company had incurred a loss of 38 cents per share.As...

ALLO : 1.0900 (-1.80%)
AGEN : 3.79 (+3.55%)
ELEV : 0.3210 (+1.29%)
ADPT : 8.84 (-2.75%)
Iovance's Q1 Earnings & Sales Miss, Stock Slides 39% on '25 View Cut

Iovance Biotherapeutics, Inc. IOVA incurred a first-quarter 2025 loss of 36 cents per share, wider than the Zacks Consensus Estimate of a loss of 25 cents. In the year-ago quarter, the company reported...

BEAM : 17.24 (+0.12%)
IOVA : 1.7500 (-0.28%)
ELEV : 0.3210 (+1.29%)
ADPT : 8.84 (-2.75%)
Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y

Perrigo PRGO reported adjusted earnings of 60 cents per share in the first quarter of 2025, beating the Zacks Consensus Estimate of 56 cents. The reported figure increased 107% year over year, primarily...

PBYI : 3.25 (-2.99%)
ELEV : 0.3210 (+1.29%)
PRGO : 26.40 (-1.90%)
NTLA : 9.46 (+2.83%)
JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook

Jazz Pharmaceuticals JAZZ reported first-quarter 2025 adjusted earnings of $1.68 per share, which significantly missed the Zacks Consensus Estimate of $4.51. This miss was largely due to higher operating...

JAZZ : 107.82 (-0.42%)
PBYI : 3.25 (-2.99%)
ELEV : 0.3210 (+1.29%)
NTLA : 9.46 (+2.83%)
Elevation Oncology Plunges 42% on Ending Development of Lead Drug

Shares of Elevation Oncology ELEV plunged more than 40% yesterday after reporting disappointing data from a phase I study on its lead pipeline drug EO-3021 for treating advanced, unresectable or metastatic...

CTMX : 2.13 (+4.41%)
ETNB : 9.65 (+0.42%)
ELEV : 0.3210 (+1.29%)
ANIP : 57.27 (-3.06%)
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year

/CNW/ -- As 2025 begins, the American Association for Cancer Research (AACR) recently published forecasts from experts showcasing transformative advances in...

ONCY : 0.4019 (-4.54%)
ELEV : 0.3210 (+1.29%)
ORIC : 5.95 (+1.36%)
ADPT : 8.84 (-2.75%)
NEO : 7.28 (-1.62%)
ONC.TO : 0.56 (-3.45%)
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down

Alkermes plc ALKS reported adjusted earnings from continuing operations of 73 cents per share for third-quarter 2024, which missed the Zacks Consensus Estimate of 78 cents. The company had reported adjusted...

CSTL : 15.89 (-0.81%)
ELEV : 0.3210 (+1.29%)
FATE : 1.2000 (+2.56%)
ALKS : 30.05 (-1.57%)
5 Biotech Stocks Under $10 With Multibagger Potential

As the biotech industry continues to redefine the healthcare landscape, here are five penny biotech stocks poised for meteoric growth in this evolving industry.

$SPX : 5,842.01 (-0.04%)
RZLT : 3.90 (-2.74%)
TRVI : 6.03 (-2.43%)
ELEV : 0.3210 (+1.29%)
CRDL : 1.0700 (+0.94%)
ADCT : 2.2300 (+13.20%)
Up 825% So Far in 2024, Can This Penny Stock Go Any Higher?

Despite its outsized year-to-date gains, Wall Street expects this breakout penny stock to soar 55% higher, on average.

$SPX : 5,842.01 (-0.04%)
ELEV : 0.3210 (+1.29%)
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:AMGN),(NASDAQ:AMAM),(NASDAQ:ELEV),(NASDAQ:NKTX) EQNX::TICKER_END

ONCY : 0.4019 (-4.54%)
NKTX : 1.7650 (+3.82%)
AMAM : 28.00 (+0.07%)
ELEV : 0.3210 (+1.29%)
ONC.TO : 0.56 (-3.45%)
AMGN : 271.90 (+0.21%)

Business Summary

Elevation Oncology Inc. is a clinical stage biopharmaceutical company. It focused on the development of precision medicines for patients with genomically defined cancers. Elevation Oncology Inc. is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 0.3557
2nd Resistance Point 0.3429
1st Resistance Point 0.3319
Last Price 0.3210
1st Support Level 0.3081
2nd Support Level 0.2953
3rd Support Level 0.2843

See More

52-Week High 4.3300
Fibonacci 61.8% 2.7604
Fibonacci 50% 2.2755
Fibonacci 38.2% 1.7906
Last Price 0.3210
52-Week Low 0.2210

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar